Gram-positive bacterial infections remain a serious challenge for infectious disease practitioners. Many gram-positive organisms are developing new methods of antibiotic resistance, thus rendering our standard antimicrobial agents ineffective. Penicillin G resistance, methicillin-resistant Staphylococcus aureus and recently, a laboratory strain of vancomycin-resistant S aureus have become catalysts in the search for effective alternatives in the treatment of gram-positive bacterial infections. This review will briefly describe an investigational agent (investigational in the US, although used widely overseas) that has been very successful in treating gram-positive bacterial infections. The antibiotic, named teicoplanin. (Merrell-Dow Pharmaceuticals) may be approved for release in the United States in the future. Originally known as teichomycin A, teicoplanin is a glycopeptide antibiotic, chemically similar to the vancomycin-ristocetin antibiotic group. Teicoplanin was discovered following the fermentation process of Actinoplanes teichomyceticus The antibiotic has a linear heptapeptide structure and weighs approximately 2000 daltons.